Verona Pharma plc (NASDAQ: VRNA ) is just three quarters into the launch of its chronic obstructive pulmonary disease (COPD) drug Ohtuvayre (ensifentrine), but the blockbuster drug discussion doesn't seem farfetched. When I last covered the nameScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disc ...